The approval makes COPD the sixth indication for the blockbuster treatment and makes Dupixent the first available biologic for the condition. As per a 27 September press announcement, Dupixent ...
The 26,905 people who indicated experiencing these symptoms completed questionnaires ... and the other half to lung specialists and asthma/COPD educators (specially trained nurses or respiratory ...